Eme M. Coerver
Amsterdam, NH 1081HV, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
Journal: Journal of neurology
Published: June 16, 2025
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: July 02, 2024
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Journal: Multiple sclerosis and related disorders
Published: November 29, 2023
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: February 07, 2023
The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 28, 2021
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: January 29, 2021
Natalizumab discontinuation in a Dutch real-world cohort.
Journal: Multiple sclerosis and related disorders
Published: January 21, 2021
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 05, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026